Allarity Therapeutics, Inc. announced a new employment agreement for Chief Financial Officer Jeffrey S. Ervin on December 3, 2025, granting him an annual salary of $367,700 and RSUs valued at $160,000. This update follows his initial part-time role starting July 1, 2025, and includes a potential performance bonus of up to 30%.